EGFR-TKI靶向治疗联合全身化疗治疗Ⅳ期肺腺癌的效果观察

Effect of EGFR-TKI targeted therapy combined with systemic chemotherapy on stage IV lung adenocarcinoma

目的:探讨表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)靶向治疗联合全身化疗治疗Ⅳ期肺腺癌的临床效果。方法:回顾性分析2019年4月至2022年4月信阳市中心医院收治的82例Ⅳ期肺腺癌患者的临床资料。按照随机数字表法将患者分为对照组与观察组,每组41例。对照组采用单纯靶向治疗,观察组在对照组治疗基础上联合全身化疗。比较两组近期疗效、血清肿瘤标志物[癌胚抗原(CEA)、细胞角蛋白19片段抗原21-1(CYFRA21-1)及神经元特异性烯醇化酶(NSE)]水平及不良反应发生率。结果:观察组疾病控制率(90.24%,37/41)高于对照组(70.73%,29/41),P<0.05。治疗后,观察组血清CEA、CYBFR21-1及NSE水平均低于对照组(P均<0.05)。观察组不良反应发生率(24.39%,10/41)与对照组(19.51%,8/41)比较差异未见统计学意义(P>0.05)。结论:EGFR-TKI靶向联合全身化疗治疗Ⅳ期肺腺癌,能提高近期疗效,降低肿瘤标志物水平,且安全性高。

Objective To investigate the effect of epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)targeted therapy combined with systemic chemotherapy in the treatment of stage IV lung adenocarcinoma.Methods The clinical data of 82 patients with stage IV lung adenocarcinoma treated in Xinyang Central Hospital from April 2019 to April 2022 were retrospectively analyzed.According to the random number table method,the selected patients were divided into control group and observation group,with 41 cases in each group.The control group was treated by targeted therapy alone,and the observation group was treated by chemotherapy based on the treatment of the control group.The short-term efficacy,levels of serum tumor markers,including carcinoembryonic antigen(CEA),cytokeratin fragment antigen 21-1(CYBFR21-1)and neuron specific enolase(NSE),and incidence of adverse reactions of the two groups were compared.Results The disease control rate of the observation group(90.24%,37/41)was higher than that of the control group(70.73%,29/41),P<0.05.After treatment,the levels of serum CEA,CYBFR21-1 and NSE in the observation group were lower than those in the control group(all P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group(24.39%,10/41)and the control group(19.51%,8/41),P>0.05.Conclusions EGFR-TKI targeted therapy combined with systemic chemotherapy for stage IV lung adenocarcinoma can improve the short-term efficacy and reduce the levels of tumor markers,with good safety.